Great news, which should remind some investors of this companies potential. Plenty of patience needed but what a ride this could be. A big well done to Alistar and the team.
Abingdon RNS this morning statement with regards to our LFT.
Currently in the process of transferring two COVID-19 Antigen tests into routine manufacture - Avacta plc's AffiDx® SARS-CoV-2 lateral flow test, and Vatic Health's KnowNow™ saliva COVID-19 antigen test.
Great update and a number of positive steps made. Should start to see very positive share price move. GLA
Whilsts this is amusing, its also tragically so true.
https://mobile.twitter.com/politicsjoe_uk/status/1366326929935245314
Great update and progress to full production. Has been disappointing the drop in share price over the last 5 months but we have seen the bottem and should start seeing a nice climb over the next few months. Should be entering a period of regular positive production updates.
A few owe mystic Sujood an apology.
Sujood could you please pick me some lottery numbers.
Soleboy thanks for your interesting posts.
On this bb we have constant spats and deramping on Avacta and Alistair Smith which clogs up the board, but the fact remains top scientists have come onboard and are excited about the Affimer technology.
We also have multiple large pharmaceutical companies with licencing agreements to utilise Avactas Affimers and see the massive potential of this technology. These scientists and companies see and understand the technology and potential far more than myself or other posters.
I wish I was more patient, but I have faith in Alistair Smith, his team and Avacta to deliver the technology and far greater financial rewards.
GLA
Ps use the filter button
It has always been my concern that Avacta should not be over reliant on uk Government, with their shambolic handling of the pandemic and smoke and mirrors with the handing out of contracts. We again see from the Abingdon RNS this morning another example of this. They seem to dragging their feet and not be supporting British companies with the urgency needed to support the pandemic.
They do seem to favour foreign companies I wonder if they helped with BoJo's flat
Whilst many have critised Alistair Smith on this BB for the speed of bringing our LFT to market, this again shows the difficulties of working with this government. This is why I believe that Alistair has pitched this perfectly and is bringing our test to market in Europe, but has left the door open to supply the UK, IF this government can get their act together.
My advice to Alistair if we get a contract with UK Government is to get the cash before he hands over the LFT.
GLA
Great presentation yesterday from Avacta. Just had another listen.
Not long to wait now for CE marking and confirmation of orders which are likely to increase over the next few month.
Whilst there was some clarity over who will be initially producing our test there remains secrecy over others that may be involved. One name that wasn't mentioned yesterday was Medusa19, we know that they have been creating capacity to produce up to 50million tests per month. Avacta are still on the Medusa website stating the test is coming soon. I think they will play a big role in increasing production and getting production up to the higher numbers in yesterdays presentation.
GLA
Well done to Avacta with great results. Not only is this the gold standard LFT, remember its a nasal swab rather than a brain tickler which makes it alot easier to use.
It was said that the biggest issue was going to be production and supply hence why some manufacturing partnerships have been set up. We are clearly going to sell everything we can make and government's will be keen to get contracts with Avacta. What an exciting couple of months with further news on capacity and contracts. Well done to those long term holders who have kept the faith.
What investors need to remember about investing in Avacta when plagued with derampers and negative posts, is;
Abcam Plc
Biokit
Mologic
Bruker
Astrea Bioseperation
LG Chem Life Sciences
Integumen
Cytiva
Adeptrix
Daewoong
ADC Therapeutics
Point Bispham
All the above pharmaceutical companies wanting to use Avactas Affimer technology, all these experts have faith in Affimers and their potential. If this doesn't instill you confidence then something is wrong , they have far great knowledge and understanding and are investing and paying to be involved and partnering Avacta. Keep the faith and wait patiently for Alistair to give us an update. If the test is as good as Alistair has repeatedly stated, countries will be fighting for the best test or access to Avactas technolical advantage.
GLA
Panorama tonight goes undercover inside a lab analysing Covid-19 tests. Could be an interesting watch.
I understand Alistair Smith has stopped late this evening, he is producing an Affimer to block Paul Hills voice.
He needs it sharpish as CE and orders RNS will be out in the next couple of weeks and he wants to be able to get a word in at the next VOX interview.
HMS Nasal
Its going to be a big boat once CE marking and orders come flooding in. For those fortunate to sail in her.
I'm sure I recall Paul Hill saying that the next VOX interview would be recorded on Monday, but may come out on Tuesday. If thats the case then I am expecting another very positive RNS either :
Monday at 7AM
Monday later at 2pm (for the Yanks)
Tuesday at 7AM
So don't be too disappointed on Monday if its not there first thing, we know is its coming and very soon and will lift the share price higher.
GLA
What a great week with further news updates from Avacta. Can it be like buses and get a third turning up this week.
Cannot be long now till we get an update on BAMs and with another VOX interview with Alistair Smith planned for Monday to discuss BAMs and take off agreements, are we likely to get it before then.
Great time to be heavily invested in Avacta and the opportunities for Affimer technology just keeps increasing, just like the share price.
GLA
Avacta Group plc
("Avacta" or "the Group")
Diagnostic Licensing Deal with Biokit
Royalty bearing license agreement to develop and commercialise an Affimer®-based in-vitro diagnostic test
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that it has entered into a license agreement with Biokit, a Werfen Company, to incorporate Affimer® reagents into a Biokit in-vitro diagnostic (IVD) product.
Biokit is recognised and renowned as a Centre of Excellence with consolidated experience worldwide in research, development and manufacturing of assays and biomaterial solutions for IVD use.
The license agreement follows an extensive evaluation by Biokit of certain Affimer reagents to detect a key analyte. Under the terms of the agreement Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners a diagnostic immunoassay for this analyte.
Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals. Financial details of the agreement were not disclosed.
Dr Alastair Smith, Chief Executive of Avacta Group commented:
"I am delighted to have established this partnership with Biokit, a world-renowned IVD company, which further validates the Affimer reagent platform for diagnostics. Avacta's diagnostics business model combines development of a wholly owned pipeline of products, including the SARS-CoV-2 rapid antigen test, with licensing of Affimer reagents to diagnostic development partners such as Biokit.
Biokit will develop an automated clinical assay using the Affimer reagents that Avacta has developed for them and I look forward to the successful conclusion of that development process and product launch. There is also potential for the partnership between our two companies to continue and expand to include other diagnostic targets and future Affimer-based IVDs."
Dr Marta Palicio, Innovation Director of Biokit commented:
"Biokit is very pleased to have reached this agreement with Avacta. The agreement will increase the competitiveness of our customized assay offering for our partners. Avacta's technology also enables us to innovate our assays with new reagents like Affimer® reagents, an alternative to antibodies. We can now move onto the next stage of development, incorporation of this technology into new products. We hope this is the first of many assays containing Affimer® reagents which will be developed by Avacta".
Avacta Group plc
("Avacta" or "the Group")
Avacta's Rapid Antigen Test is Confirmed to Detect SARS-CoV-2 New Variants
Avacta's AffiDX® SARS-CoV-2 lateral flow test detects both B117 'Kent' and D614G variants of the virus
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or 'Kent', variant, and the D614G variant, as well as the original strain.
The SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these variants are more infectious, and therefore more rapidly transmissible, and have the potential to become dominant strains.
Early on in the pandemic a variant referred to as D614G appeared, which rapidly became the dominant strain globally1. The B117 variant, which was first observed in Kent, is prevalent in the UK, has been found in more than 50 countries and, according to Professor Sharon Pea**** (Professor of Public Health and Microbiology at Cambridge University) is likely to become the next dominant strain globally2.
Avacta has carried out analytical tests with the spike proteins isolated from both the B117 and D614G variants, and has confirmed that its AffiDX® SARS-CoV-2 rapid antigen lateral flow test detects both of these variants as well as the original strain.
Dr Alastair Smith, Chief Executive of Avacta Group commented:
"We are pleased to confirm that Avacta's rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK. We have also shown that our test detects the D614G variant, the current dominant global strain.
We will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us. Since the Affimer reagents we use in Avacta's range of SARS-CoV-2 tests do not bind in the region of the spike protein where the dominant mutations appear, we do not anticipate that the performance of the tests will be affected.
Now that we have developed a robust lateral flow test architecture, we can easily insert Affimer reagents that that can be very rapidly developed for new variants if necessary, and indeed in response to any other future pandemic virus.
Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved."
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
Disclaimer: AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test not currently for
Its definitely the Vox interview effect and how close we are. LTH fully understand the Avacta opportunities and know whats coming very soon, the recent interview with Alistair Smith has been very reasuring as to Avacta's journey and where we are. There is not much to say or link up now, we know we will find out soon enough. It also seems the derampers realise they are wasting their time on here, as we can all just rerun the vox interview and be smug that we got in early.
GLA
A funny day with all the hype over the weekend and then the RNS this morning. We have gone from no news to press articles and updates but are still in the dark over many issues.
Boris didn't give much away either in Parliament or this evening addressing the nation. There was not much reference to LFT. I was not expecting Avacta's to be named, but I thought there would be more emphasis on testing and how they are going to rolling it out.
Im sure that the government are so focused on the success of the vaccine rollout and trying to recover their disastrous handling of the pandemic. Now they have a good news story, they don't want to change the focus from vaccine rollout to testing just yet , as it might affect the take up of the vaccine.
Also their awarding of multi mullion pound contracts at the moment is very sensitive. I don't think the government will now sign any contract until the LFT is fully evaluated and CE marked.
The RNS reads that Avacta are fustrated at the delays which have been out of their control particularly PD.
So many questions need answers , but I don't think we will have too long to wait . TU hopefully this week and news on BAMs very soon, the CE sign off on our LFT and they will be fighting to get a contact with us.